Thermo Fisher Scientific Product — Cost of revenues increased by 4.7% to $3.32B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.7%, from $3.17B to $3.32B. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests margin compression due to rising input costs or manufacturing inefficiencies, while a decrease relative to revenue suggests improved operational leverage or better supply chain management.
This metric captures the direct costs associated with manufacturing, sourcing, and delivering the physical products sold...
Comparable to Cost of Goods Sold (COGS) in manufacturing-heavy industries, this metric is standard for benchmarking production efficiency against other life science equipment manufacturers.
tmo_segment_product_revenues_cost_of_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $3.35B | $3.56B | $3.52B | $3.29B | $3.29B | $3.29B | $3.29B | $3.17B | $3.32B |
| QoQ Change | — | +6.1% | -1.1% | -6.4% | +0.0% | +0.0% | +0.0% | -3.7% | +4.7% |
| YoY Change | — | — | +4.9% | -7.4% | -6.4% | — | — | -3.7% | +4.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.